Gilead's Trodelvy fails to meet main goal in lung cancer trial
Updates share movement, adds analyst comment in paragraph 5
By Deena Beasley
Jan 22 (Reuters) -Gilead Sciences GILD.O said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC) in a late-stage study, sending its shares down more than 10%.
The California-based drugmaker was testing Trodelvy, which belongs to a class of treatments known as antibody drug conjugates, in patients with both squamous and non-squamous NSCLC - the most common type of lung cancer.
Roughly 230,000 adults in the United States were estimated to be diagnosed with lung cancer in 2023, and NSCLC accounts for 81% of all those diagnoses, according to the American Society of Clinical Oncology.
The Phase 3 study, aimed at expanding the use of the treatment, showed that patients with NSCLC who were treated with Trodelvy lived longer than those given chemotherapy, Gilead said. However, the difference was not statistically significant, it added.
The data raises questions on Trodelvy's use as a later-line of treatment, BMO Capital Markets analyst Evan Seigerman said. He added that there was still opportunity for Gilead to command market share as an initial treatment for NSCLC.
Gilead is also conducting Phase 2 and 3 trials of Trodelvy in combination with Keytruda as an initial treatment for NSCLC patients.
The current trial involved 603 patients with metastatic or advanced NSCLC that had worsened during or after the current standard treatment regimen of platinum-based chemotherapy and a checkpoint inhibitor, such as Merck's MRK.N Keytruda.
Gilead said it plans to discuss the results with regulators and present the full data at an upcoming medical meeting.
The trial showed a more than three-month survival benefit for a sub-group of patients who had not responded to their last prior checkpoint inhibitor treatment, Gilead said.
The company plans to explore potential pathways to understand the drug's effect for those patients.
The Phase 3 front-line trial is currently enrolling patients and results will not be available for "a couple of years at least," Merdad Parsey, Gilead's chief medical officer, told Reuters.
The latest data "gives us continued confidence in Trodelvy's potential in metastatic NSCLC, and in our broader lung cancer clinical development program," he said.
Parsey said Trodelvy's safety profile was consistent with prior studies, with the most common adverse events being neutropenia, or low white blood cell counts, and diarrhea.
Trodelvy is currently approved by U.S. regulators for patients with two specific types of advanced breast cancer and bladder cancers. It brought in sales of $765 million in the first nine months of last year.
Reporting by Deena Beasley and Pratik Jain; Editing by Christopher Cushing and Anil D'Silva
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
